Genezen and Optieum Partner to Manufacture Lentiviral Vectors for Novel Glioblastoma CAR-T Therapy
Genezen will provide technology transfer, process development, and cGMP manufacturing of lentiviral vectors for Optieum's OPTF01, a CAR-T therapy targeting glioblastoma.
First Patient Dosed in Groundbreaking Optogenetic Gene Therapy Trial for Retinitis Pigmentosa
Restore Vision Inc. has initiated the world's first clinical trial of optogenetic gene therapy using "Chimeric Rhodopsin" technology for treating retinitis pigmentosa patients.
© Copyright 2025. All Rights Reserved by MedPath